ZA201202718B - Pyrrolo[2,3-d]pyrimidine compounds - Google Patents
Pyrrolo[2,3-d]pyrimidine compoundsInfo
- Publication number
- ZA201202718B ZA201202718B ZA2012/02718A ZA201202718A ZA201202718B ZA 201202718 B ZA201202718 B ZA 201202718B ZA 2012/02718 A ZA2012/02718 A ZA 2012/02718A ZA 201202718 A ZA201202718 A ZA 201202718A ZA 201202718 B ZA201202718 B ZA 201202718B
- Authority
- ZA
- South Africa
- Prior art keywords
- pyrrolo
- pyrimidine compounds
- pyrimidine
- compounds
- Prior art date
Links
- 150000004943 pyrrolo[2,3-d]pyrimidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25203909P | 2009-10-15 | 2009-10-15 | |
| PCT/IB2010/054447 WO2011045702A1 (en) | 2009-10-15 | 2010-10-01 | Pyrrolo[2,3-d] pyrimidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201202718B true ZA201202718B (en) | 2012-12-27 |
Family
ID=43413616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2012/02718A ZA201202718B (en) | 2009-10-15 | 2012-04-13 | Pyrrolo[2,3-d]pyrimidine compounds |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US8633206B2 (enExample) |
| EP (1) | EP2488524B1 (enExample) |
| JP (1) | JP5629324B2 (enExample) |
| KR (1) | KR20120083452A (enExample) |
| CN (1) | CN102574860A (enExample) |
| AP (1) | AP2012006192A0 (enExample) |
| AR (1) | AR078635A1 (enExample) |
| AU (1) | AU2010308028A1 (enExample) |
| CA (1) | CA2776028C (enExample) |
| CL (1) | CL2012000795A1 (enExample) |
| CO (1) | CO6531451A2 (enExample) |
| CR (1) | CR20120164A (enExample) |
| CU (1) | CU20120059A7 (enExample) |
| DO (1) | DOP2012000080A (enExample) |
| EA (1) | EA201290147A1 (enExample) |
| EC (1) | ECSP12011855A (enExample) |
| ES (1) | ES2426407T3 (enExample) |
| IL (1) | IL218802A0 (enExample) |
| IN (1) | IN2012DN02577A (enExample) |
| MA (1) | MA33670B1 (enExample) |
| MX (1) | MX2012004379A (enExample) |
| NI (1) | NI201200053A (enExample) |
| PE (1) | PE20121077A1 (enExample) |
| PH (1) | PH12012500583A1 (enExample) |
| TN (1) | TN2012000146A1 (enExample) |
| TW (1) | TWI398444B (enExample) |
| UY (1) | UY32947A (enExample) |
| WO (1) | WO2011045702A1 (enExample) |
| ZA (1) | ZA201202718B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2015151857A (ru) | 2008-12-02 | 2019-01-15 | Уэйв Лайф Сайенсес Джапан, Инк. | Способ синтеза модифицированных по атому фосфора нуклеиновых кислот |
| SI2411395T1 (sl) | 2009-03-23 | 2013-07-31 | Glenmark Pharmaceuticals S.A. | Furopirimidindionski derivati kot TRPA1 modulatorji |
| EA023857B1 (ru) | 2009-03-23 | 2016-07-29 | Гленмарк Фармасеутикалс С.А. | Сочлененные производные пиримидиндионов в качестве модуляторов trpa1 |
| MX342945B (es) | 2009-07-06 | 2016-10-18 | Ontorii Inc * | Profármacos de ácido nucleico novedosos y métodos de uso de los mismos. |
| TW201111385A (en) * | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| JP5739446B2 (ja) * | 2009-12-18 | 2015-06-24 | ファイザー・インク | ピロロ［２，３−ｄ］ピリミジン化合物 |
| US10428019B2 (en) * | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
| EP3248982A1 (en) | 2011-07-19 | 2017-11-29 | Wave Life Sciences Ltd. | Thiosulfonate reagents for the synthesis of functionalized nucleic acids |
| AU2012295802B2 (en) | 2011-08-12 | 2017-03-30 | Nissan Chemical Industries, Ltd. | Tricyclic heterocyclic compounds and JAK inhibitors |
| CN104661664B (zh) | 2012-07-13 | 2020-07-03 | 波涛生命科学有限公司 | 手性控制 |
| CA2879023C (en) | 2012-07-13 | 2017-03-28 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| CA2879066C (en) | 2012-07-13 | 2019-08-13 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant |
| RS56810B1 (sr) * | 2012-07-17 | 2018-04-30 | Glaxosmithkline Ip No 2 Ltd | Indolkarbonitrili kao selektivni modulatori androgen receptora |
| CN103896946B (zh) * | 2012-12-28 | 2018-04-03 | 浙江导明医药科技有限公司 | 用于预防及治疗多种自身免疫疾病的新化合物 |
| WO2014118388A1 (en) | 2013-02-04 | 2014-08-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for assaying jak2 activity in red blood cells and uses thereof |
| ES2755130T3 (es) | 2013-02-08 | 2020-04-21 | Nissan Chemical Corp | Compuesto de pirrolopiridina tricíclico, e inhibidor de JAK |
| EP3290421B1 (en) * | 2013-02-22 | 2019-01-02 | Pfizer Inc | Combination of pyrrolo [2, 3 -d]pyrimidine derivatives with one or more additional agents as inhibitors of janus- related kinases (jak) |
| KR20160002857A (ko) | 2013-05-02 | 2016-01-08 | 에프. 호프만-라 로슈 아게 | CB2 수용체 작용제로서의 피롤로[2,3-d]피리미딘 유도체 |
| US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| MX2016009290A (es) | 2014-01-16 | 2017-02-28 | Wave Life Sciences Ltd | Diseño quiral. |
| EP2924026A1 (en) | 2014-03-28 | 2015-09-30 | Novartis Tiergesundheit AG | Aminosulfonylmethylcyclohexanes as JAK inhibitors |
| ES2744213T3 (es) | 2014-05-14 | 2020-02-24 | Nissan Chemical Corp | Compuesto tricíclico e inhibidor de JAK |
| JP6585158B2 (ja) | 2014-08-12 | 2019-10-02 | ファイザー・インク | ヤヌスキナーゼの阻害に有用なピロロ［２，３−ｄ］ピリミジン誘導体 |
| US9926327B2 (en) * | 2016-02-16 | 2018-03-27 | Zoetis Services Llc | Process for preparing 7H-pyrrolo[2,3-D]pyrimidine compounds |
| CN107098908B (zh) * | 2016-02-23 | 2021-01-08 | 欣凯医药科技(上海)有限公司 | 一种吡咯并嘧啶类化合物的制备方法和应用 |
| WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
| EP3610264A1 (en) | 2017-04-13 | 2020-02-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| CN111499641B (zh) * | 2019-01-30 | 2021-06-04 | 格格巫（珠海）生物科技有限公司 | 一种jak抑制剂及其制备方法 |
| IL264854A (en) * | 2019-02-14 | 2020-08-31 | Bahat Anat | Spt5 inhibitors and methods of use thereof |
| CN114025758A (zh) * | 2019-07-01 | 2022-02-08 | 钱立刚 | P2x7r拮抗剂 |
| CN114761011B (zh) * | 2019-08-26 | 2024-06-14 | 肯沃斯公司 | 用作jak1抑制剂的取代的(7h-吡咯并[2,3-d]嘧啶-4-基)氨基化合物 |
| KR20220088699A (ko) | 2019-09-27 | 2022-06-28 | 디스크 메디슨, 인크. | 골수섬유증 및 관련 상태의 치료 방법 |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| CN115246833B (zh) * | 2021-04-27 | 2024-08-13 | 洛阳惠中兽药有限公司 | 一种奥拉替尼化合物及其中间体化合物的制备方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS50087B (sr) * | 1998-06-19 | 2009-01-22 | Pfizer Products Inc., | Pirolo (2,3-d) pirimidin jedinjenja |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| CZ303875B6 (cs) | 1999-12-10 | 2013-06-05 | Pfizer Products Inc. | Pyrrolo[2,3-d]pyrimidinová sloucenina a farmaceutická kompozice s jejím obsahem |
| EA006153B1 (ru) * | 2000-06-26 | 2005-10-27 | Пфайзер Продактс Инк. | СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИММУНОДЕПРЕССАНТОВ |
| US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| EP1572649A2 (en) | 2002-11-21 | 2005-09-14 | Pfizer Products Inc. | 3-amino-piperidine derivatives and processes for their preparation |
| JP5010917B2 (ja) * | 2003-08-29 | 2012-08-29 | エグゼリクシス， インコーポレイテッド | ｃ−Ｋｉｔ調節因子および使用方法 |
| JP2007511596A (ja) | 2003-11-17 | 2007-05-10 | ファイザー・プロダクツ・インク | 癌の治療において有用なピロロピリミジン化合物 |
| US20070270588A1 (en) | 2004-03-05 | 2007-11-22 | Taisho Pharmaceutical Co., Ltd. | Pyrrolopyrimidine Derivatives |
| EP1773826A4 (en) * | 2004-07-02 | 2009-06-03 | Exelixis Inc | MODULATORS OF C-MET AND THEIR METHOD OF USE |
| AR054416A1 (es) * | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| RU2485106C2 (ru) | 2005-06-08 | 2013-06-20 | Райджел Фамэсьютикэлз, Инк. | Соединения, проявляющие активность в отношении jak-киназы (варианты), способ лечения заболеваний, опосредованных jak-киназой, способ ингибирования активности jak-киназы (варианты), фармацевтическая композиция на основе указанных соединений |
| EP2251341A1 (en) | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
| MX2008001334A (es) | 2005-07-29 | 2008-03-24 | Pfizer Prod Inc | Derivados de pirrolo [2,3-d]pirimidina, sus intermedios y sintesis. |
| NZ567133A (en) | 2005-09-30 | 2011-07-29 | Vertex Pharma | Deazapurines useful as inhibitors of janus kinases |
| MY167260A (en) | 2005-11-01 | 2018-08-14 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US8962643B2 (en) | 2006-02-24 | 2015-02-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| CN101395134B (zh) * | 2006-03-02 | 2011-08-31 | 安斯泰来制药有限公司 | 17β-羟类固醇脱氢酶5型抑制剂 |
| WO2009049028A1 (en) | 2007-10-09 | 2009-04-16 | Targegen Inc. | Pyrrolopyrimidine compounds and their use as janus kinase modulators |
| WO2009115084A2 (de) | 2008-03-20 | 2009-09-24 | Schebo Biotech Ag | Neue pyrrolopyrimidin-derivate und deren verwendungen |
| PT2384326E (pt) * | 2008-08-20 | 2014-06-09 | Zoetis Llc | Compostos de pirrolo[2,3-d]pirimidina |
-
2010
- 2010-10-01 EP EP10771200.2A patent/EP2488524B1/en active Active
- 2010-10-01 MX MX2012004379A patent/MX2012004379A/es unknown
- 2010-10-01 AP AP2012006192A patent/AP2012006192A0/xx unknown
- 2010-10-01 KR KR1020127012417A patent/KR20120083452A/ko not_active Ceased
- 2010-10-01 AU AU2010308028A patent/AU2010308028A1/en not_active Abandoned
- 2010-10-01 CN CN2010800461239A patent/CN102574860A/zh active Pending
- 2010-10-01 CA CA2776028A patent/CA2776028C/en not_active Expired - Fee Related
- 2010-10-01 WO PCT/IB2010/054447 patent/WO2011045702A1/en not_active Ceased
- 2010-10-01 EA EA201290147A patent/EA201290147A1/ru unknown
- 2010-10-01 IN IN2577DEN2012 patent/IN2012DN02577A/en unknown
- 2010-10-01 JP JP2012533715A patent/JP5629324B2/ja not_active Expired - Fee Related
- 2010-10-01 ES ES10771200T patent/ES2426407T3/es active Active
- 2010-10-01 PH PH1/2012/500583A patent/PH12012500583A1/en unknown
- 2010-10-01 PE PE2012000447A patent/PE20121077A1/es not_active Application Discontinuation
- 2010-10-12 TW TW099134779A patent/TWI398444B/zh not_active IP Right Cessation
- 2010-10-13 US US12/903,554 patent/US8633206B2/en active Active
- 2010-10-14 AR ARP100103751A patent/AR078635A1/es not_active Application Discontinuation
- 2010-10-15 UY UY0001032947A patent/UY32947A/es not_active Application Discontinuation
-
2012
- 2012-03-22 IL IL218802A patent/IL218802A0/en unknown
- 2012-03-23 DO DO2012000080A patent/DOP2012000080A/es unknown
- 2012-03-29 TN TNP2012000146A patent/TN2012000146A1/fr unknown
- 2012-03-30 CR CR20120164A patent/CR20120164A/es unknown
- 2012-03-30 CL CL2012000795A patent/CL2012000795A1/es unknown
- 2012-04-09 NI NI201200053A patent/NI201200053A/es unknown
- 2012-04-13 MA MA34774A patent/MA33670B1/fr unknown
- 2012-04-13 ZA ZA2012/02718A patent/ZA201202718B/en unknown
- 2012-04-13 CU CU20120059A patent/CU20120059A7/es unknown
- 2012-04-18 CO CO12064126A patent/CO6531451A2/es not_active Application Discontinuation
- 2012-04-27 EC ECSP12011855 patent/ECSP12011855A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201202718B (en) | Pyrrolo[2,3-d]pyrimidine compounds | |
| ZA201101701B (en) | Pyrrolo[2,3-d]pyrimidine compounds | |
| IL257410A (en) | Pyrazolo [1, 5 – a ] pyrimidines as antiviral agents | |
| ZA201104853B (en) | 2,5-diamino-substituted pyrido[4,3-d]pyrimidines as autotaxin inhibitors against cancer | |
| EP2624698A4 (en) | Furo [3,2-D] PYRIMIDINE COMPOUNDS | |
| ZA201307839B (en) | Pyrazolo[4,3-d] pyrimidines useful as kinase inhibitors | |
| PH12013501402A1 (en) | Mesoionic Pyrido [1,2 -A] Pyrimidine Pesticides | |
| PT2794611T (pt) | Pirazolo[1,5-a]pirimidinas como agentes antivirais | |
| ZA201002334B (en) | Imidazo | |
| ZA201200982B (en) | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors | |
| IL210172A0 (en) | Substituted pyrimidin-4-one derivatives | |
| ZA201105896B (en) | [1,2,4] triazolo [1,5-a] pyridines as kinase inhibitors | |
| IL201446A0 (en) | Heteroarylamide pyrimidone compounds | |
| ZA201406323B (en) | Triazolo[4,5-d]pyrimidine derivatives | |
| IL229993A (en) | 8 - Alkoxy [1,2,4] triazolo [5,1 – c] pyrimidine– 2 | |
| ZA201101861B (en) | Compositions with and process for methylmorpholin-substituted pyrido [2,3-d] pyrimidines | |
| EP2511276A4 (en) | Pyrrolo [2,3-D] pyrimidine derivative | |
| IL206666A0 (en) | N-PHENYLIMIDAZO[1,2-a]PYRIDINE-2- | |
| IL226228A0 (en) | derivation of pyrazino[3,2–d]isooxazole | |
| IL206668A0 (en) | N-PHENYLIMIDAZO[1,2-a]PYRIDINE-2- | |
| ZA201105528B (en) | 2-morpholino-pyrido[3,2-d]pyrimidines | |
| AU2019204281A1 (en) | Antiviral compounds | |
| AU2011355362B2 (en) | 5-([1,2,3]Triazole-4-yl)-7H-pyrrolo[2,3-d]pyrimidine derivatives | |
| IL192335A0 (en) | Antiviral compounds | |
| GB0816600D0 (en) | Antiviral compounds |